use
adjuv
candid
vaccin
phase
safeti
immunogen
trial
ten
vaccine
serum
sampl
display
neutral
titer
vesicular
stomat
viru
vsv
hcv
pseudotyp
serum
sampl
test
neutral
titer
human
immunodefici
viru
hiv
hcv
pseudotyp
serum
sampl
test
neutral
titer
cell
culturegrown
hcv
genotyp
neutral
serum
sampl
increas
affin
level
display
higher
specif
activ
level
wellcharacter
epitop
especi
hypervari
region
purifi
hcv
glycoprotein
vaccin
adjuv
among
healthi
volunt
antibodymedi
pseudotyp
neutral
neutral
hcv
genotyp
grown
cell
cultur
examin
character
humor
immun
respons
associ
hcv
vaccin
serum
sampl
vaccine
also
examin
avid
subclass
distribut
reactiv
linear
epitop
method
random
doubleblind
placebocontrol
studi
complet
approv
saint
loui
univers
institut
review
board
immun
includ
dose
purifi
chines
hamster
ovarian
cellderiv
fulllength
recombin
glycoprotein
hcv
genotyp
along
adjuv
novarti
differ
volunt
group
volunt
group
vaccin
time
week
mg
per
vaccin
dose
adjuv
sixteen
volunt
vaccin
receiv
placebo
control
serum
sampl
collect
volunt
differ
time
point
heat
inactiv
natur
antibodi
respons
character
avid
index
hcv
antibodi
determin
enzymelink
immunosorb
elut
assay
use
sodium
thiocyan
chaotrop
agent
four
biotinyl
peptid
repres
known
linear
b
cell
epitop
glycoprotein
synthes
anaspec
use
determin
epitopespecif
antibodi
respons
enzymelink
immunosorb
assay
elisa
wilcoxon
sign
rank
test
perform
statist
analys
use
prism
softwar
version
graphpad
pseudotyp
deriv
vesicular
stomat
viru
vsv
human
immunodefici
viru
hiv
gener
use
hcv
envelop
glycoprotein
genotyp
genbank
access
use
surrog
viru
neutral
sulfat
sialyl
lipid
use
vsvhcv
pseudotyp
assay
inhibit
potenti
effect
residu
uptak
parent
g
glycoprotein
backbon
serial
dilut
antibodi
ad
predetermin
titer
vsvhcv
pseudotyp
plaqueform
unit
per
reaction
hivhcv
pseudotyp
rel
luciferas
unit
per
reaction
incub
h
addit
cell
monolay
cell
wash
level
infect
determin
describ
elsewher
hcv
genotyp
clone
grown
immort
human
hepatocyt
ihh
describ
elsewher
rna
quantifi
realtim
polymeras
chain
reaction
prism
realtim
thermocycl
abi
use
hcv
analytespecif
reagent
asr
abbott
viru
growth
also
measur
fluoresc
focu
form
assay
neutral
cell
culturegrown
hcv
presenc
absenc
vaccine
serum
determin
infect
ihh
human
monoclon
antibodi
hcv
glycoprotein
use
neutral
posit
control
assay
repeat
time
result
read
independ
differ
individu
result
examin
serum
sampl
volunt
complet
studi
determin
neutral
activ
hcv
surrog
viru
prevaccin
serum
sampl
volunt
display
neutral
titer
test
vsvhcv
pseudotyp
ten
serum
sampl
immun
volunt
display
detect
specif
neutral
activ
level
vsvhcv
pseudotyp
close
studi
five
serum
sampl
titer
titer
seven
serum
sampl
placebo
control
volunt
titer
remain
serum
sampl
placebo
control
volunt
exhibit
detect
neutral
titer
exclud
increas
dosag
level
candid
vaccin
correl
increas
neutral
antibodi
titer
among
volunt
receiv
vaccin
statist
signific
number
serum
sampl
volunt
vaccin
lowest
dose
vaccin
antigen
mg
test
posit
vsvhcv
pseudotyp
neutral
follow
vaccin
vaccine
serum
sampl
subsequ
test
hivhcv
pseudotyp
hcv
grown
cell
cultur
neutral
one
vaccine
serum
sampl
test
titer
titer
titer
hivhcv
pseudotyp
ten
vaccine
serum
sampl
test
display
neutral
hcv
genotyp
grown
cell
cultur
two
serum
sampl
titer
titer
titer
cell
culturegrown
viru
interestingli
serum
sampl
neutral
vsvhcv
pseudotyp
wherea
display
neutral
activ
hivhcv
pseudotyp
overal
neutral
activ
level
hivhcv
pseudotyp
higher
neutral
assay
employ
observ
vaccine
serum
sampl
viru
neutral
titer
hcv
grown
cell
cultur
could
ascertain
serum
sampl
use
lower
dilut
disrupt
monolay
ihh
titer
clear
higher
dilut
hand
serum
sampl
placebo
control
volunt
fail
neutral
surrog
viru
hcv
grown
cell
cultur
thu
result
suggest
agreement
among
detect
neutral
activ
level
surrog
model
viru
grown
cell
cultur
although
titer
vari
like
differ
readout
antibodi
respons
hcv
envelop
glycoprotein
among
serum
sampl
vaccin
volunt
placebo
control
volunt
primarili
distribut
immunoglobulin
subclass
differ
observ
immunoglobulin
g
subclass
neutral
serum
sampl
nonneutr
serum
sampl
avid
index
reflect
combin
function
affin
antibodi
form
polyclon
humor
immun
respons
consid
paramet
describ
efficaci
antibodi
elimin
neutral
antigen
vaccine
serum
sampl
investig
correl
neutral
activ
level
avid
index
antibodi
avid
index
evalu
use
sodium
thiocyan
major
serum
sampl
obtain
week
fourth
vaccin
dose
vaccin
volunt
display
high
avid
index
acquisit
high
avid
index
serum
sampl
volunt
vaccin
escal
dose
immunogen
indic
antibodi
matur
correl
level
immunogen
use
analysi
serum
sampl
individu
time
cours
studi
indic
increas
antibodi
avid
index
establish
third
dose
immunogen
affect
dosag
level
immunogen
deliv
vaccin
humanderiv
monoclon
antibodi
encompass
amino
acid
residu
recent
describ
neutral
hcv
pseudotyp
viru
grown
cell
cultur
genotyp
induct
broadli
crossreact
immun
respons
hypervari
region
glycoprotein
suggest
gener
protect
immun
hand
linear
antibodi
epitop
protein
encompass
amino
acid
residu
epitop
epitop
identifi
recent
epitop
implic
hcv
neutral
wherea
bind
antibodi
epitop
suggest
disrupt
viru
neutral
associ
epitop
antibodi
evalu
reactiv
level
vaccine
serum
sampl
dilut
linear
epitop
elisa
fifteen
serum
sampl
exhibit
increas
optic
densiti
conserv
epitop
nine
posit
serum
sampl
conserv
epitop
display
neutral
activ
hcv
pseudotyp
vaccine
serum
sampl
similarli
examin
reactiv
epitop
twentyon
serum
sampl
vaccin
volunt
display
measur
reactiv
level
increas
optic
densiti
compar
match
preimmun
control
sampl
eleven
serum
sampl
display
detect
neutral
activ
level
vsvhcv
pseudotyp
twentythre
figur
venn
diagram
repres
uniqu
share
epitop
recognit
hepat
c
viru
envelop
glycoprotein
serum
sampl
volunt
vaccin
reactiv
level
panel
serum
sampl
vaccine
test
dilut
biotinyl
peptid
repres
linear
epitop
immobil
avidinco
enzymelink
immunosorb
assay
elisa
plate
epitop
encompass
amino
acid
residu
ilethrglyhisargmetalatrpaspmetmetmetasntrpseroh
hypervari
region
epitop
encompass
amino
acid
residu
gluthrhisvalthrglyglyseralaglyhisthrvalserglyphevalserleuleualaproglyalalysglnasnoh
epitop
encompass
amino
acid
residu
glnleuileasnthrasnglysertrphisileasnserthralaoh
epitop
encompass
amino
acid
residu
leuasnthrglytrpleualaglyleuphetyrglnhislyspheoh
immobil
ng
per
well
avidinco
elisa
plate
plate
incub
dilut
test
serum
sampl
overnight
wash
bound
antibodi
detect
ad
streptavidinhorseradish
peroxidaseconjug
antibodi
human
immunoglobulin
peroxidas
substrat
color
intens
measur
absorb
nm
result
display
reactiv
increas
optic
densiti
compar
match
preimmun
placebo
control
serum
sampl
consid
posit
overlap
region
repres
serum
sampl
concomitantli
recogn
epitop
serum
sampl
recogn
epitop
nonneutr
epitop
also
shown
b
serum
sampl
display
neutral
activ
label
white
vaccine
serum
sampl
display
reactiv
epitop
increas
optic
densiti
compar
serum
sampl
control
volunt
serum
sampl
display
neutral
activ
vsvhcv
pseudotyp
percentag
vaccine
serum
sampl
display
posit
reaction
epitop
significantli
higher
observ
among
serum
sampl
patient
chronic
hcv
infect
addit
vaccine
serum
sampl
react
epitop
optic
densiti
compar
preimmun
placebo
control
serum
sampl
vaccine
serum
sampl
also
display
reactiv
epitop
figur
preimmun
placebo
control
serum
sampl
exhibit
detect
level
reactiv
synthet
peptid
use
posit
serum
sampl
display
neutral
titer
vsvhcv
pseudotyp
vaccine
serum
sampl
character
neutral
nonneutr
evalu
antibodi
affin
specif
epitop
serum
sampl
abil
neutral
hcv
display
higher
epitopespecif
affin
display
nonneutr
serum
sampl
figur
howev
unlik
affin
display
identifi
neutral
epitop
specif
affin
neutral
activ
disrupt
epitop
presenc
sodium
thiocyan
compar
group
interestingli
level
antibodi
affin
epitop
significantli
higher
epitop
test
even
presenc
sodium
thiocyan
result
suggest
antibodi
strong
affin
neutral
epitop
associ
may
correl
level
hcv
neutral
discuss
studi
highlight
find
signific
number
serum
sampl
vaccine
display
high
avid
hcv
approxim
half
serum
sampl
react
serum
sampl
also
recogn
linear
epitop
envelop
glycoprotein
observ
statist
signific
correl
level
neutral
activ
dose
immunogen
among
sampl
vaccin
volunt
result
suggest
avid
hcv
antibodi
increas
prime
boost
cours
vaccin
furthermor
increas
avid
index
week
fourth
vaccin
dose
suggest
select
stimul
highavid
memori
b
cell
neutral
activ
level
vaccine
serum
sampl
vsvhcv
pseudotyp
also
similar
middl
time
point
test
week
dose
data
shown
indic
avid
abil
neutral
establish
rel
quickli
vaccin
function
import
avid
matur
fulli
reflect
figur
antibodi
affin
linear
epitop
hepat
c
viru
hcv
envelop
glycoprotein
serum
sampl
volunt
vaccin
neutral
nonneutr
vaccine
serum
sampl
analyz
affin
synthet
peptid
repres
hcv
epitop
hypervari
region
epitop
epitop
immobil
enzymelink
immunosorb
assay
elisa
plate
biotinconjug
synthet
peptid
immobil
avidinco
elisa
plate
antibodi
affin
level
synthet
peptid
determin
ad
individu
neutral
serum
sampl
gray
box
nonneutr
serum
sampl
white
box
dilut
presenc
vari
concentr
sodium
thiocyan
nascn
epitop
epitop
bound
antibodi
detect
horseradish
peroxidaseconjug
antibodi
human
immunoglobulin
peroxidas
substrat
reactiv
level
compar
absenc
nascn
result
level
reactiv
epitop
express
percentag
specif
affin
calcul
optic
densiti
presenc
nascn
divid
optic
densiti
absenc
nascn
multipli
result
shown
mean
valu
standard
deviat
independ
experi
box
indic
upper
lower
quartil
line
insid
box
indic
median
valu
p
valu
determin
wilcoxon
sign
rank
test
low
hcv
neutral
activ
level
antibodi
vaccine
serum
sampl
use
differ
hcv
pseudotyp
surrog
model
hcv
genotyp
clone
grown
cell
cultur
analyz
neutral
activ
vaccine
serum
sampl
pseudotyp
advantag
disadvantag
vsvderiv
pseudotyp
easi
readout
viru
plaqu
format
use
extens
laboratori
result
verifi
hcv
grown
cell
cultur
furthermor
highli
sensit
luciferas
assay
use
hivderiv
pseudotyp
also
exhibit
neutral
activ
serum
sampl
vaccin
volunt
appar
higher
serum
dilut
result
investig
studi
indic
higher
degre
sensit
antiserummedi
inhibit
hivbas
system
compar
vsvbase
system
hcv
grown
cell
cultur
similar
observ
note
use
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
lentiviru
assay
comparison
nativ
sarscov
neutral
assay
lack
strong
correl
presenc
antibodi
epitop
epitop
vaccine
serum
sampl
neutral
hcv
indic
abil
gener
neutral
respons
wholli
reliant
antibodi
bind
previous
character
epitop
gener
neutral
antibodi
respons
conserv
epitop
vaccin
prepar
would
prefer
would
limit
potenti
genotyp
divers
viru
escap
immun
surveil
mean
select
pressur
recombin
cell
culturegrown
viru
deriv
genotyp
envelop
sequenc
replac
genotyp
backbon
neutral
reciproc
dilut
use
serum
sampl
patient
chronic
infect
patient
h
whose
sampl
sequenc
deriv
result
indic
potenti
high
neutral
titer
patient
chronic
hcv
infect
howev
extens
longitudin
studi
neutral
antibodi
patient
h
hivhcv
pseudotyp
found
neutral
activ
serum
sampl
taken
specif
envelop
gene
sequenc
use
assay
indic
immun
varianc
within
singl
individu
could
dramat
alter
antibodi
respons
individu
neutral
epitop
thu
diverg
viral
protein
use
assay
may
contribut
differ
antibodi
respons
distinct
mechan
hcv
entri
escap
antibodymedi
neutral
may
also
key
determin
progress
infect
process
